Calcineurin: A poorly understood regulator of muscle mass
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
This review will discuss the existing literature that has examined the role of calcineurin (CnA) in the regulation of skeletal muscle mass in conditions associated with hypertrophic growth or atrophy. Muscle mass is determined by the balance between protein synthesis and degradation which is controlled by a number of intracellular signaling pathways, most notably the insulin/IGF/phosphatidylinositol 3-kinase (PI3K)/Akt system. Despite being activated by IGF-1 and having well-described functions in the determination of muscle fiber phenotypes, calcineurin (CnA), a Ca2+-activated serine/threonine phosphatase, and its downstream signaling partners have garnered little attention as a regulator of muscle mass. Compared to other signaling pathways, the relatively few studies that have examined the role of CnA in the regulation of muscle size have produced discordant results. The reasons for these differences is not obvious but may be due to the selective nature of the genetic models studied, fluctuations in the endogenous level of CnA activity in various muscles, and the variable use of CnA inhibitors to inhibit CnA signaling. Despite the inconsistent nature of the outcomes, there is sufficient direct and indirect evidence to conclude that CnA plays a role in the regulation of skeletal muscle mass.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., & Moraes, C. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911570106 · Cited by 600 · cited 1×
“Similarly, Wenz and colleagues (Wenz et al., 2009) found that overexpression of PGC-1 α prevented sarcopenia and muscle wasting associated with metabolic disorders.”
RetractedSandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012 · cited 2×
“When insulin or IGF-1 signaling is low or impaired (e.g., diabetes, kidney disease), the activities of the FOXOs increase, resulting in upregulation of the ubiquitin-proteasome and autophagy-lysosome systems (Mammucari, Milan, 2007, Sandri et al., 2004, Zhao et al., 2007, Zheng, Ohkawa, 2010).”
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546 · cited 1×
“CnA supports the slow fiber phenotype, in part, by maintaining PGC-1 α through activation of the MEF2 and NFAT transcription factors (Lin et al., 2002).”
FoxO3 Controls Autophagy in Skeletal Muscle In Vivo
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S. J., Di Lisi, R., Sandri, C., Zhao, J., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.001 · Cited by 1,953 · cited 2×
“, 2007), the autophagy-lysosome system (Mammucari et al., 2007), and select members of the calpain and caspase families (Franch and Price, 2005, Lecker and Mitch, 2011, Powers et al.”
Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1032913100 · Cited by 1,952
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · cited 2×
“…results from activation of intracellular proteolytic systems including the ubiquitin-proteasome pathway (Hudson et al., 2012, Lecker et al., 2006, Lecker et al., 2004, Sacheck et al., 2007), the autophagy-lysosome system (Mammucari et al., 2007), and select members of the calpain and caspase…”
Self-citationMechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492
Zhao, J., Brault, J. J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.004 · Cited by 1,489 · cited 1×
“When insulin or IGF-1 signaling is low or impaired (e.g., diabetes, kidney disease), the activities of the FOXOs increase, resulting in upregulation of the ubiquitin-proteasome and autophagy-lysosome systems (Mammucari, Milan, 2007, Sandri et al., 2004, Zhao et al., 2007, Zheng, Ohkawa, 2010).”
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010083 · Cited by 1,234
Skeletal muscle hypertrophy and atrophy signaling pathways
Glass, D. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.018 · Cited by 1,106 · cited 1×
“Details of these processes can be found in a number of excellent reviews (Glass, 2005, Jackman and Kandarian, 2004, Lecker, Jagoe, 2004, Powers et al., 2005, Schiaffino et al., 2013, Ventadour and Attaix, 2006, Workeneh and Mitch, 2010).”
The Molecular Basis of Skeletal Muscle Atrophy
Jackman, R. W., & Kandarian, S. C. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00579.2003 · Cited by 1,008 · cited 2×
“It is widely accepted that skeletal muscle atrophy is a combinatorial process that involves both a decrease in muscle protein synthesis and an increase in protein degradation (Eley and Tisdale, 2007, Jackman and Kandarian, 2004, Powers et al., 2007).”
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974 · cited 1×
“…PGC-1 α , a transcriptional coactivator that regulates various aspects of skeletal muscle metabolism, is reduced in skeletal muscle during conditions associated with FOXO activation and atrophy (Arany, 2008, Mootha et al., 2003, Patti et al., 2003, Roberts-Wilson et al., 2010, Sandri et al., 2006).”
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models
Schiaffino, S., & Mammucari, C. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-4 · Cited by 816 · cited 2×
“Inhibition of the pathway, genetically or pharmacologically, results in the same atrophy-related responses that occur in conditions associated with muscle wasting (Price et al., 2010, Sacheck et al., 2004, Schiaffino and Mammucari, 2011).”
Sacheck, J. M., Hyatt, J. K., Raffaello, A., Thomas Jagoe, R., Roy, R. R., Reggie Edgerton, V., Lecker, S. H., & Goldberg, A. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-6604com · Cited by 585 · cited 1×
“…of intracellular proteolytic systems including the ubiquitin-proteasome pathway (Hudson et al., 2012, Lecker et al., 2006, Lecker et al., 2004, Sacheck et al., 2007), the autophagy-lysosome system (Mammucari et al., 2007), and select members of the calpain and caspase families (Franch and…”
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506 · cited 1×
“Moreover, well known side-effects associated with sustained use of CnA inhibitors include nephrotoxicity, new onset diabetes mellitis, and peripheral neuropathy (English et al., 2002, Heisel et al., 2004) which put patients at higher risks of developing muscle atrophy.”
Mechanisms of disuse muscle atrophy: role of oxidative stress
Powers, S. K., Kavazis, A. N., & DeRuisseau, K. C. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00469.2004 · Cited by 368 · cited 1×
“Details of these processes can be found in a number of excellent reviews (Glass, 2005, Jackman and Kandarian, 2004, Lecker, Jagoe, 2004, Powers et al., 2005, Schiaffino et al., 2013, Ventadour and Attaix, 2006, Workeneh and Mitch, 2010).”
Zheng, B., Ohkawa, S., Li, H., Roberts‐Wilson, T. K., & Price, S. R. (2010) · The FASEB Journal · doi:10.1096/fj.09-151480 · Cited by 145 · cited 2×
“…al., 2006, Lecker et al., 2004, Sacheck et al., 2007), the autophagy-lysosome system (Mammucari et al., 2007), and select members of the calpain and caspase families (Franch and Price, 2005, Lecker and Mitch, 2011, Powers et al., 2012, Smuder et al., 2012, Whidden et al., 2010, Zheng et al., 2010).”
Self-citation
Cited by
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications
Ostrovidov, S., Hosseini, V., Ahadian, S., Fujie, T., Parthiban, S. P., Ramalingam, M., Bae, H., Kaji, H., & Khademhosseini, A. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0534 · Cited by 302
Hudson, M. B., Woodworth-Hobbs, M. E., Zheng, B., Rahnert, J. A., Blount, M. A., Gooch, J. L., Searles, C. D., & Price, S. R. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00266.2013 · Cited by 137
“For example, transgenic overexpression of activated Cn does not cause skeletal muscle hypertrophy, whereas stimulation of Cn signaling by IGF-I or -adrenergic agonists induces muscle growth and overexpression of NFATc1 produces muscle hypertrophy (12).”
Self-citationLi, S., Pan, H., Tan, C., Sun, Y., Song, Y., Zhang, X., Yang, W., Wang, X., Li, D., Dai, Y., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.013 · Cited by 106
“For example, elevated [Ca2+]i can activate Ca 2+-sensitive calcineurin via Ca2+/calmodulin (Hudson and Price, 2013) or mediate the activation of myocyte enhancer factor 2 (Molkentin et al., 1998) and thereby can cause HCM.”
Background
Metadata
- Authors
- Hudson, M. B., & Price, S. R.
- Venue
- The International Journal of Biochemistry & Cell Biology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 45
- Issue
- 10
- Pages
- 2173-2178
- ISSN
- 1357-2725 (ISSN-L)
- OpenAlex
- W1990026683
- Cited by
- 67
- References
- 18
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.